Table 1.
Characteristics of P. aeruginosa Positive Patients in Pre- and Post-Pandemic Periods
| Variables | Pre-Pandemic (n = 131) | Post-Pandemic (n = 185) |
|---|---|---|
| Demographics | ||
| Age (year) | 75.8±9.7 | 76.2±9.2 |
| Gender (Male n/%) | 99 (75.6) | 154 (83.2) |
| Smoke (Yes, n/%) | 68 (51.9) | 63 (48.1) |
| Give up smoke (n/%) | 51 (75) | 93 (84.5) |
| Main diagnosis of respiratory diseases | ||
| CAP | 109 (83.2) | 157 (84.9) |
| COPD | 82 (62.6) | 129 (69.7) |
| Asthma | 5 (3.8) | 5 (2.7) |
| Interstitial lung disease | 6 (4.6) | 9 (4.9) |
| Comorbidities | ||
| Cardiovascular disease n (%) | 90 (28.8) | 120 (30.7) |
| Liver disease n (%) | 13 (9.9) | 14 (7.6) |
| Nervous diseases n (%) | 13 (4.2) | 20 (5.1) |
| Kidney disease n (%) | 13 (9.9) | 29 (15.7) |
| Diabetes mellitus n (%) | 44 (14.1) | 63 (16.1) |
| Cancers n (%) | 8(2.6) | 5 (1.3) |
| Laboratories | ||
| Leukocytes (109/L) | 5.75 (4.7, 7.0) | 7.29 (5.6, 9.7)*** |
| Eosinophils (109/L) | 0.20 (0.15, 0.31) | 0.05(0.01, 0.08)*** |
| Neutrophils (109/L) | 3.72(2.9, 4.8) | 5.38 (4.0, 8.1)*** |
| Lymphocytes (109/L) | 1.13(0.9, 1.6) | 0.99 (0.7, 1.4)*** |
| Monocytes (109/L) | 0.41(0.3, 0.6) | 0.5(0.3, 0.6) |
| Basophils (109/L) | 0.04(0.02, 0.05) | 0.02(0.01, 0.04)*** |
| Platelets (109/L) | 149(113, 192) | 147(113, 191) |
| Hemoglobin (g/L) | 130(119, 143) | 130(120, 142) |
| Hs-CRP (mg/L) | 11.7(4.2, 30.9) | 22.8(6.1, 73.1)** |
| Clinical symptoms and signs | ||
| Temperature (>37.3°C, n (%)) | 17 (12.98) | 15 (8.11) |
| Respiration (>20 per min) | 78 (59.5) | 116 (62. 7) |
| Blood pressure (>140/80 mmHg) | 14 (10.7) | 18 (9.7%) |
| Cough | 108 (82.4) | 163 (88.1) |
| Dyspnea | 48 (36.6) | 76 (41.1) |
| Sputum production | 76 (58.0) | 112 (60.5) |
| Chest distress | 22 (16.8) | 33 (17.8) |
| Fatigue | 43 (32.8) | 59 (31.9) |
| Poor sleep | 39 (29.8) | 52 (28.1) |
Notes: Pre-pandemic year: January 01, 2019-December 31, 2019; post-pandemic year: May 1, 2020-April 30, 2021.**P<0.01,***P<0.001.
Abbreviations: CAP, community acquired pneumonia; COPD, chronic obstructive pulmonary disease; Hs-CRP, high-sensitivity C-reactive protein.